Perioperative medicine & outcomes
Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial
Primary result · Mortality within 90 daysResult — go to the resultEstimated difference 0.04% 95% CI −0.05%-0.42%Authors' conclusion
In this secondary analysis of a cluster randomized trial comparing aspirin with enoxaparin following hip or knee arthroplasty, there was no significant between-group difference in mortality within 90 days when either drug was used for VTE prophylaxis.
Study context
- Population
- Adults (≥18 years) undergoing any hip or knee arthroplasty at 31 Australian hospitals, 2019–2020
- Participants
- 23,458 adults · 31 hospitals
- Comparison
- Aspirin vs enoxaparin for venous thromboembolism (VTE) prophylaxis
- Aspirinn = 14,156
- Enoxaparinn = 9,302reference
- Primary endpoint
- Mortality
- Follow-up
- 90 days
Methodological detailsplanned secondary analysis, cluster randomized, crossover, registry-nested, multicentre
- Planned secondary analysis
- Cluster randomized
- Crossover
- Registry-nested
- Multicentre
Primary result
Mortality within 90 days
Estimated difference
0.04%
95% CI −0.05%-0.42%
By group
Aspirin vs Enoxaparin
estimated difference 0.04% (95% CI −0.05%-0.42%)
As reported in the abstract
Further findings
| Outcome | Aspirin | Enoxaparin | Estimated difference (95% CI) | |
|---|---|---|---|---|
| Mortality within 90 days, nonfracture diagnosis (subgroup, n = 21 148) | 0.49% | 0.41% | 0.05% (−0.67% to 0.76%) | |
| −1−0.500.51Difference (linear scale) |
Original publication
Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial. JAMA Netw Open. Published 1 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →